Report Overview

The EU Liver cancer drugs market size stood at USD 180 million in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

Hepatic or liver cancer is one of the most commonly prevalent types of cancer. It is known for its aggressive nature and poor survival rate. Certain medical conditions such as Hepatitis B and C viral infections, type 2 diabetes, excess body weight, and liver cirrhosis are known to be the leading causes for the onset of liver cancer. Consumption of alcohol, tobacco is acknowledged to exponentially increase the risk of liver cancer. Approximately 29 million people in the EU still suffer from one of the other chronic liver cancer. Therefore, the liver cancer medication market is anticipated to become an active ground for competition in the near future



Market Growth Drivers

Factors such as the rising incidence of liver cancer, excessive alcohol consumption, and growing research activities for developing novel treatments coupled with increasing government funding are driving the EU liver cancer drug market. Increasing research activities in the development of novel drug and therapeutic systems are anticipated to propel the EU liver cancer drug market. Whereas, high research and development cost, as well as stringent drug approval process and adverse side effects associated with cancer treatment medications, are projected to hamper the market growth